Allergy & Immunology
Study | Public health policies should recommend introducing peanut products to infants at 4-6 months of age to prevent peanut allergy
20 Mar, 2023 | 13:33h | UTCCommentary: Expert reaction to research on giving peanut products to babies – Science Media Centre
Related study: Early Introduction of Allergenic Foods Can Prevent Food Allergies in High Risk Infants
Related Guidelines:
AAP Updated Recommendations for Dietary Interventions to Prevent Atopic Disease
Timing of introduction of allergenic solids for infants at high risk – Canadian Paediatric Society
Commentary from the author on Twitter
Latest paper from #LEAPStudy is now published in @JACIonline. We have looked at what happens if peanut products are introduced into the infant diet at different ages across the whole population. https://t.co/zpOlrNHOSihttps://t.co/xDIgYjezyS
More details below. @GoAllergy 1/12 pic.twitter.com/jY5MvdJ2AZ— Graham Roberts (@ProfGRoberts) January 12, 2023
Cohort Study | Leukotriene-receptor antagonist use during pregnancy not linked to neuropsychiatric events in offspring
17 Mar, 2023 | 12:56h | UTCCommentary: In utero exposure to asthma medication not tied to risks of neurodevelopmental disorders – MDedge
International consensus statement on allergy and rhinology: allergic rhinitis
16 Mar, 2023 | 13:19h | UTC
Drug allergy | A 2022 practice parameter update
3 Mar, 2023 | 13:59h | UTCDrug allergy: A 2022 practice parameter update – The Journal of Allergy and Clinical Immunology
Antibiotic allergy de-labeling: a pathway against antibiotic resistance
23 Feb, 2023 | 13:12h | UTCAntibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance – Antibiotics
Related:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
M-A | Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis
16 Feb, 2023 | 15:04h | UTCSummary: The article examined the prevalence Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) associated with antibiotics worldwide. The analysis included 38 studies involving 2,917 patients, which showed that 28% of SJS/TEN cases were associated with antibiotics. Among antibiotic-associated SJS/TEN, the sulfonamide class was associated with 32% of cases, followed by penicillins, cephalosporins, fluoroquinolones, and macrolides.
Article: Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis – JAMA Dermatology (free for a limited period)
*Note: This summary was created through the collaboration of a medical editor and ChatGPT.
Phase 2 RCT | Effects of Difelikefalin in notalgia paresthetica
13 Feb, 2023 | 12:42h | UTCPhase 2 Trial of Difelikefalin in Notalgia Paresthetica – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Phase 2 Trial Finds Difelikefalin Could Prove Useful in Notalgia Paresthetica – HCP Live
Difelikefalin Improves Itch Intensity in Notalgia Paresthetica – HealthDay
Commentary on Twitter
In a phase 2 trial in notalgia paresthetica, oral difelikefalin treatment resulted in modestly reduced itch as compared with placebo. https://t.co/MQMO7z4o0W pic.twitter.com/2iaCgb3c93
— NEJM (@NEJM) February 8, 2023
RCT | Effectiveness of Mycophenolate Mofetil among patients with progressive IgA nephropathy
10 Feb, 2023 | 13:52h | UTC
Commentary on Twitter
RCT: For patients with IgA nephropathy at high risk of disease progression, addition of mycophenolate to optimized supportive care reduced risk of kidney function loss, vs supportive care alone. https://t.co/xjyD3hseG7 pic.twitter.com/BlQiXkyBLn
— JAMA Network Open (@JAMANetworkOpen) February 6, 2023
RCT | Methylprednisolone vs. immunoglobulins equally effective in PIMS temporally associated with SARS-CoV-2
8 Feb, 2023 | 12:42h | UTC
Phase 2b RCT | An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis
8 Feb, 2023 | 12:22h | UTCAn anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study – The Lancet (link to abstract – $ for full-text)
News Release: New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results – Mount Sinai Health System
Commentary: Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis – HealthDay
Commentary on Twitter:
Just published in The Lancet: Patients treated w- rocatinlimab, an anti-OX40 antibody, had progressive improvements in atopic dermatitis, which was maintained in most pts after treatment stopped. @EmmaGuttman PI. Details: https://t.co/PpiKsy0ra0 pic.twitter.com/6ghKpsLQsZ
— Mount Sinai Dermatology (@MSHSDerm) December 10, 2022
Guideline | Urticaria management
6 Feb, 2023 | 13:25h | UTC
Patients labeled as nonallergic after initial tests for penicillin allergy may develop resensitization afterwards
2 Feb, 2023 | 15:03h | UTCResensitization in suspected penicillin allergy – Allergy
Video summary: Resensitisation in suspected penicillin allergy
Commentary: Patients should be retested for penicillin resensitization before being deemed nonallergic – Healio (free registration required)
Related:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
Commentary on Twitter
Doña et al. Resensitization in suspected #penicillinallergy
Read ? https://t.co/irMhv07kN5
Video abstract of this article ? https://t.co/JIzDlQROYN
Read all recent papers published in #Allergy on #drugallergies ? https://t.co/jUxpXPlxKB@mariajtorresj #Allergy_journal pic.twitter.com/eIB1TdDqPI
— Allergy EAACI (@AllergyEaaci) November 15, 2022
M-A | Metabolic adverse events associated with systemic corticosteroid therapy
24 Jan, 2023 | 14:10h | UTC
RCT | Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis
15 Jan, 2023 | 20:07h | UTC
Commentary on Twitter
Does blocking the IL-13 cytokine w/ lebrikizumab combined w/ topical therapy provide clinical benefit in atopic eczema? This study reflecting real-world use patterns suggests a benefit. https://t.co/apUvYO3Jqv
— JAMA Dermatology (@JAMADerm) January 13, 2023
Phase 1-2 study | Lentiviral gene therapy for artemis-deficient SCID
12 Jan, 2023 | 12:59h | UTCLentiviral Gene Therapy for Artemis-Deficient SCID – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Infant gene therapy is a breakthrough for Artemis-SCID patients – University of California – San Francisco
Commentary on Twitter
Severe combined immunodeficiency caused by mutations in the gene encoding a DNA-repair enzyme called Artemis is difficult to treat. This study involving 10 patients supports a gene-therapy approach. https://t.co/SCpZjOQtMW pic.twitter.com/VRYOje6UPV
— NEJM (@NEJM) December 22, 2022
SR | Skin care interventions in infants for preventing eczema and food allergy.
12 Dec, 2022 | 12:23h | UTCSkin care interventions in infants for preventing eczema and food allergy – Cochrane Library
Summary: Skin care interventions for preventing eczema and food allergy – Cochrane Library
Commentary on Twitter
Read our newest review on skin care interventions in infants for preventing eczema and food allergy! https://t.co/o8HtBXRVM5 pic.twitter.com/BPzsjJZvTf
— Cochrane Skin (@CochraneSkin) November 15, 2022
M-A | Allergen immunotherapy for atopic dermatitis.
9 Dec, 2022 | 13:24h | UTC
Improving antimicrobial stewardship with penicillin allergy testing: a review of current practices and unmet needs.
27 Nov, 2022 | 22:25h | UTCRelated:
M-A: Most patients with allergy to Penicillin can be given Cefazolin
Podcast: A Clinical Pharmacologist’s Perspective on Penicillin Allergy
Study: Development and Validation of a Penicillin Allergy Clinical Decision Rule
NICE: Double Check Patients with ‘Penicillin Allergy’ to Avoid Increased MRSA Risk
SR | Interventions for the long‐term prevention of hereditary angioedema attacks.
27 Nov, 2022 | 22:12h | UTCInterventions for the long‐term prevention of hereditary angioedema attacks – Cochrane Library
Summary: Drug treatments for the prevention of attacks of hereditary angioedema – Cochrane Library
Commentary on Twitter
New #CochraneEvidence – Interventions for the long‐term prevention of #HereditaryAngioedema attacks #HAE @CochraneUK @CochraneLibrary @US_HAEA @UCSDHealth @HAEDAY @VSGBI @ChariteBerlin https://t.co/jYYjmG1eGH pic.twitter.com/2z522Bw5iZ
— CochraneVasc (@CochraneVasc) November 7, 2022
RCT | Efficacy and safety of Remibrutinib, a novel BTK inhibitor, for chronic spontaneous urticaria.
23 Nov, 2022 | 13:37h | UTC
M-A | Long-term outcomes of turbinate surgery in patients with allergic rhinitis.
18 Nov, 2022 | 13:09h | UTCLong-term Outcomes of Turbinate Surgery in Patients With Allergic Rhinitis: A Systematic Review and Meta-analysis – JAMA Otolaryngology—Head & Neck Surgery (free for a limited period)
SR | Immunostimulants vs. placebo for preventing exacerbations in adults with chronic bronchitis or COPD.
16 Nov, 2022 | 13:34h | UTC
RCT | Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen.
8 Nov, 2022 | 12:06h | UTCEffects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial – Journal of Allergy and Clinical Immunology (link to abstract – $ for full-text)
News Release: Monoclonal antibody improves cat allergen immunotherapy – National Institutes of Health
Safety of Upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies.
19 Oct, 2022 | 14:14h | UTC
WAO/EAACI guideline for the management of hereditary angioedema.
4 Oct, 2022 | 14:34h | UTC